

RECEIVED

OCT 11 2001

TECH CENTER 1600/2900

O I P E
OCT 09 2001
US PATENT AND TRADEMARK OFFICE
JC48

| | | | |
|---|---|------------------------------------|--------------------------|
| Form PTO-1449 | US Department of Commerce Patent and Trademark Office | ATTY DOCKET NO: P-IM 4734 | SERIAL NO. 09/853,830 |
| | | APPLICANT: Arthur A. Vandenbark | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FILING DATE: May 10, 2001 | GROUP: Unassigned |

U.S. PATENT DOCUMENTS

| EXAM. INITIALS | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|----------------|-----------------|----------|------------------|-------|-----------|-------------|
| Au | 5,612,035 | 03/18/97 | Howell et al. | 424 | 185.1 | |
| | 5,614,192 | 03/25/97 | Vandenbark | 424 | 185.1 | |
| | 5,776,459 | 07/07/98 | Vandenbark | 424 | 185.1 | |
| | 5,837,246 | 11/17/98 | Howell et al. | 424 | 185.1 | |
| | 5,856,446 | 01/05/99 | Weiner et al. | 530 | 356 | |
| | 5,858,968 | 01/12/99 | Weiner et al. | 514 | 3 | |
| | 5,869,093 | 02/09/99 | Weiner et al. | 424 | 451 | |
| | 5,939,281 | 08/17/99 | Lehmann et al. | 435 | .94 | |
| | 6,019,971 | 02/01/00 | Weiner et al. | 424 | 184.1 | |
| | 6,039,947 | 03/21/00 | Weiner et al. | 424 | 184.1 | |
| | 6,045,796 | 04/04/00 | Sriram et al. | 424 | 185.1 | |
| | 6,090,387 | 07/18/00 | Howell et al. | 424 | 185.1 | |
| | 6,113,903 | 09/05/00 | Albertini et al. | 424 | 185.1 | |
| | 6,159,470 | 12/12/00 | Howell et al. | 424 | 73.1 | |
| | 6,197,926 | 03/06/01 | Gaur et al. | 530 | 303 | |
| | 6,218,132 | 04/17/01 | Spack et al. | 435 | 7.24 | |
| Au | 6,221,352 | 04/24/01 | Howell et al. | 424 | 139.1 | |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
| Campy | 2-20-03 |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



OCT 11 2001

TECH CENTER 1600/2900

Page 2 of 2

| | | |
|---|------------------------------------|--------------------------|
| Form PTO 1449 US Department of Commerce Patent and Trademark Office | ATTY DOCKET NO: P-IM 4734 | SERIAL NO. 09/853,830 |
| | APPLICANT: Arthur A. Vandenbark | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | FILING DATE: May 10, 2001 | GROUP: Unassigned |

| | | | | | | | |
|--|--|--|--|--|--|--|--|
| | | | | | | | |
|--|--|--|--|--|--|--|--|

FOREIGN PATENT DOCUMENTS


| EXAM. INITIALS | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION (YES/NO) |
|-------------------|--|--------------------|----------|---------|-------|---------------|-------------------------|
| CJ | | WO 94/25063 | 11/10/94 | PCT | | | |
| Cn | | WO 99/58977 | 11/18/99 | PCT | | | |
| | | EP 957359 | 11/17/99 | Europe | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

| | | |
|----|--|---|
| Ch | | Arden et al., "Human T-cell receptor variable gene segment families," <u>Immunogenetics</u> 42:455-500 (1995). |
| | | Brosterhaus et al., "Enrichment and detection of live antigen-specific CD4+ and CD8+ T cells based on cytokine secretion," <u>Eur. J. Immunol.</u> 29:4053-4059 (1999). |
| | | Choi et al., "Interaction of Staphylococcus aureus toxin "superantigens" with human T cells," <u>Proc. Natl. Acad. Sci. USA</u> 86:8941-8945 (1989). |
| Ch | | Chou et al., "Immunity to TCR peptides in multiple sclerosis," <u>J. Immunol.</u> 152:2520-2529 (1994). |

| | |
|-----------------------|-----------------------------------|
| EXAMINER <i>Ch</i> | DATE CONSIDERED <i>2-20-03</i> |
|-----------------------|-----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



OCT 11 2001

TECH CENTER 1600/2900

Page 3 of 2

| | | | |
|---|--|------------------------------------|--------------------------|
| Form PTO 1449 US Department of Commerce Patent and Trademark Office | | ATTY DOCKET NO: P-IM 4734 | SERIAL NO. 09/853,830 |
| | | APPLICANT: Arthur A. Vandenbark | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FILING DATE: May 10, 2001 | GROUP: Unassigned |

| | | |
|----|--|---|
| CM | | Cochlovius et al., "In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPIPOPE program," <i>J. Immunol.</i> 165:4731-4741 (2000). |
| | | Concannon et al., "Diversity and structure of human T-cell receptor β -chain variable region genes," <i>Proc. Natl. Acad. Sci. USA</i> 83:6598-6602 (1986). |
| | | Czerninsky et al., "Reverse ELISPOT assay for clonal analysis of cytokine production," <i>J. Immunol. Methods</i> 110:29-36 (1998). |
| | | Evavold et al., "Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands," <i>Immunology Today</i> 14:602-609 (1993). |
| | | Fairchild, "Altered peptide ligands: prospects for immune intervention in autoimmune disease," <i>Eur. J. Immunogenet.</i> 24:155-167 (1997). |
| | | Genevee et al., "An experimentally validated panel of subfamily-specific oligonucleotide primer (V α 1-w29/V β 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction," <i>Eur. J. Immunol.</i> 22:1261-1269 (1992). |
| | | Kay et al., "Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a study of the eastern cooperative oncology group (E9487)," <i>Leuk. Lymphoma</i> 33:127-133 (1999). |
| | | Kimura et al., "Sequences and repertoire of the human T cell receptor α and β chain variable region genes in thymocytes," <i>Eur. J. Immunol.</i> 17:375-383 (1987). |
| | | Mancia et al., "Characterization of the T-cell receptor V- β repertoire in Kawasaki disease," <i>Scand. J. Immunol.</i> 48:443-449 (1998). |
| CM | | Olsson et al., "Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon- γ ," <i>J. Clin. Invest.</i> 86:981-985 (1990). |

| | |
|--------------------------------|----------------------------|
| EXAMINER <i>Carlo Myers</i> | DATE CONSIDERED 2-20-03 |
|--------------------------------|----------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

OCT 11 2001

TECH CENTER 1600/2900
Page 4 of 2

| | | | |
|---|---|------------------------------------|--------------------------|
| Form PTO 1449 | US Department of Commerce Patent and Trademark Office | ATTY DOCKET NO: P-IM 4734 | SERIAL NO. 09/853,830 |
| | | APPLICANT: Arthur A. Vandenbark | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FILING DATE: May 10, 2001 | GROUP: Unassigned |

| | | |
|----|--|---|
| Ch | | Robinson, "The human T cell receptor β-chain gene complex contains at least 57 variable gene segments," <u>J. Immunol.</u> 146:4392-4397 (1991). |
| | | Savoie et al., "Use of Bonsai decision trees for the identification of potential MHC class I peptide epitope motifs," <u>Pac. Symp. Biocomput.</u> 1999:182-189 (1999). |
| CM | | Vandenbark et al., "Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial," <u>Nature Med.</u> 2:1109-1115 (1996). |
| | | |

| | |
|--------------------------------|----------------------------------|
| EXAMINER <i>(Signature)</i> | DATE CONSIDERED <i>2-20-B</i> |
|--------------------------------|----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.